骨松健骨方治疗肝肾阴虚血瘀型原发性骨质疏松症的临床研究  

Effect of Gusong Jiangu Decoction(骨松健骨方,GSJGD) on Primary Osteoporosis with Liver and Kidney Yin Deficiency and Blood Stasis Type

作　　者：毛春焕[1] 孔西建[1] 吴丹[1] 李盈盈[1] 徐健康[2] 阮海军 

机构地区：[1]河南省洛阳正骨医院/河南省骨科医院,河南洛阳471002 [2]洛阳市精神卫生中心,河南洛阳471002 [3]洛阳煤电集团有限公司医院,河南洛阳471002

出　　处：《中医药导报》2017年第14期79-82,共4页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：河南省中医药科学研究专项课题(2013zy04058);项目名称:中医中药治疗原发性骨质疏松症的研究

摘　　要：目的:研究骨松健骨方治疗肝肾阴虚血瘀型原发性骨质疏松症的临床疗效。方法:将80例肝肾阴虚血瘀型原发性骨质疏松症患者随机分为治疗组50例和对照组30例。治疗组服用骨松健骨方,对照组服用仙灵骨葆胶囊。观察治疗后两组骨痛评分、中医临床症状评分、平衡能力评分、骨代谢生化指标BALP、β-CTX、骨密度、脆性骨折发生率及安全性指标。结果:(1)临床疗效:治疗组显效率为18.8%,总有效率为89.6%,对照组显效率为16.7%,总有效率为90.0%。两组比较,差异无统计学意义(P>0.05)。(2)临床症状:与治疗前比较,两组骨痛评分、中医临床症状评分、Berg平衡量表评分均明显改善,差异均有统计学意义(P<0.05)。两组治疗后骨痛评分、中医临床症状评分、Berg平衡量表评分比较,差异均无统计学意义(P>0.05)。(3)骨代谢:治疗组治疗后,BALP、β-CTX均明显下降,差异有统计学意义(P<0.05);治疗后两组比较,治疗组BALP低于对照组,差异有统计学意义(P<0.05)。(4)骨密度及骨密度变化率:两组治疗前后腰椎BMD值、T值无明显变化,差异无统计学意义(P>0.05)。(5)脆性骨折发生率:两组治疗后骨折发生率明显下降,差异有统计学意义(P<0.05),治疗组骨折发生率下降39.6%,对照组下降36.7%。治疗后两组骨折发生率比较,差异无统计学意义(P>0.05)。结论:骨松健骨方治疗肝肾阴虚血瘀型原发性骨质疏松症具有较好临床疗效和安全性,可有效改善患者疼痛、平衡能力及中医临床症状,防止骨密度下降,降低骨转换率和脆性骨折发生率,疗效与仙灵骨葆胶囊相同。Objective： To observe the effects of Gusong Jiangu decoction （骨松健骨方, GSJGD） in the treatment of primary osteoporosis with liver and kidney yin deficiency and blood stasis type. Methods： The 80 cases with primary osteoporosis of the liver and kidney yin deficiency and blood stasis type were randomly di- vided inlo experimental group 50 cases, taking GSJGD, the control group of 30 cases, taking Xianling Gubao capsule （仙灵骨葆, XLGBC）. After treatment, the pain scores, TCM clinical symptom scores, balance ability scores, bone metabolism biochemical index BALP, beta-CTX, bone density, brittle fracture incidence and safety index changes of the two groups were observed. Results： （1） clinical observation： the effective rate of the treat- ment group was 18.8%, and the total effective rate was 89.6%, while the control group was 16.7% and 90.0% respectively, the difference was not statistically significant （P〉0.05）. （2） clinical symptoms： after treatment, the scores of bone pain score, TCM clinical symptom score and Berg balance scale of two groups were significantly improved, the difference was statistically significant （P〈0.05）; and the scores of bone pain score, clinical symp- tom score and Berg balance scale of the two groups were not statistically significant （P〉0.05）. （3） bone metabolism： after treatment, BALP, beta-CTX of treatment group were significantly decreased, the difference was statistically significant （P〈0.05）; and the treatment group BALP was lower than the control group （P〈0.05）. （4） bone mineral density and bone mineral density change rate： the BMD and T values of the lumbar spine in thetwo groups had no signifieant difference before and aiter treatment （P〉0.05）. （5） ineidenee of brittle fracture： after trealmenl the fraeture rate of the two groups deereased signifieantly （P〈0.05）, the fracture rate of the Ireatment group deereased by 39.6%, and that of the eontrol group decreased by 36.7%, there was no

关 键 词：原发性骨质疏松症 肝肾阴虚血瘀 骨松健骨方 仙灵骨葆胶囊 骨密度 骨转换率 脆性骨折 

分 类 号：R255.6[医药卫生—中医内科学]